BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31544356)

  • 1. Larotrectinib imaging response in low-grade glioma.
    Walter AW; Kandula VVR; Shah N
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28002. PubMed ID: 31544356
    [No Abstract]   [Full Text] [Related]  

  • 2. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.
    Ziegler DS; Wong M; Mayoh C; Kumar A; Tsoli M; Mould E; Tyrrell V; Khuong-Quang DA; Pinese M; Gayevskiy V; Cohn RJ; Lau LMS; Reynolds M; Cox MC; Gifford A; Rodriguez M; Cowley MJ; Ekert PG; Marshall GM; Haber M
    Br J Cancer; 2018 Sep; 119(6):693-696. PubMed ID: 30220707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory infantile high-grade glioma containing TRK-fusion responds to larotrectinib.
    Waters TW; Moore SA; Sato Y; Dlouhy BJ; Sato M
    Pediatr Blood Cancer; 2021 May; 68(5):e28868. PubMed ID: 33403813
    [No Abstract]   [Full Text] [Related]  

  • 4. Discovery of a rare
    Deland L; Keane S; Olsson Bontell T; Sjögren H; Fagman H; Øra I; De La Cuesta E; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
    Cancer Biol Ther; 2021 Mar; 22(3):184-195. PubMed ID: 33820494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lorlatinib in a Child with
    Bagchi A; Orr BA; Campagne O; Dhanda S; Nair S; Tran Q; Christensen AM; Gajjar A; Furtado LV; Vasilyeva A; Boop F; Stewart C; Robinson GW
    N Engl J Med; 2021 Aug; 385(8):761-763. PubMed ID: 34407349
    [No Abstract]   [Full Text] [Related]  

  • 6. Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma.
    König D; Hench J; Frank S; Dima L; Bratic Hench I; Läubli H
    Pharmacology; 2022; 107(7-8):433-438. PubMed ID: 35526519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an
    Mangum R; Reuther J; Bertrand KC; Chandramohan R; Kukreja MK; Paulino AC; Muzny D; Hu J; Gibbs RA; Curry DJ; Malbari F; Chintagumpala MM; Adesina AM; Fisher KE; Mack SC; Plon SE; Roy A; Parsons DW; Lin FY
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34651095
    [No Abstract]   [Full Text] [Related]  

  • 8. Amide proton transfer imaging to discriminate between low- and high-grade gliomas: added value to apparent diffusion coefficient and relative cerebral blood volume.
    Choi YS; Ahn SS; Lee SK; Chang JH; Kang SG; Kim SH; Zhou J
    Eur Radiol; 2017 Aug; 27(8):3181-3189. PubMed ID: 28116517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An automatic glioma grading method based on multi-feature extraction and fusion.
    Zhan T; Feng P; Hong X; Lu Z; Xiao L; Zhang Y
    Technol Health Care; 2017 Jul; 25(S1):377-385. PubMed ID: 28582926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower-grade gliomas: the wrong target for bevacizumab.
    Schiff D; de Groot JF
    Neuro Oncol; 2018 Nov; 20(12):1559-1560. PubMed ID: 30418659
    [No Abstract]   [Full Text] [Related]  

  • 11. "No growth" on serial MRI scans of a low grade glioma?
    Jakola AS; Moen KG; Solheim O; Kvistad KA
    Acta Neurochir (Wien); 2013 Dec; 155(12):2243-4. PubMed ID: 24146183
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment to the article: Magnetic resonance spectroscopic imaging for visualization of the infiltration zone of glioma.
    Forsting M
    Cent Eur Neurosurg; 2011 May; 72(2):70. PubMed ID: 21547882
    [No Abstract]   [Full Text] [Related]  

  • 13. Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements.
    D'Arco F; O'Hare P; Dashti F; Lassaletta A; Loka T; Tabori U; Talenti G; Thust S; Messalli G; Hales P; Bouffet E; Laughlin S
    Neuroradiology; 2018 Apr; 60(4):427-436. PubMed ID: 29383433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?
    Lee EQ; McFaline-Figueroa JR; Cloughesy TF; Wen PY
    Neuro Oncol; 2018 Jul; 20(8):1144. PubMed ID: 29955870
    [No Abstract]   [Full Text] [Related]  

  • 15. PCV in low-grade gliomas: benefit from old drugs in an evolving disease entity.
    Schiff D
    Neuro Oncol; 2016 Jun; 18(6):755-6. PubMed ID: 27174998
    [No Abstract]   [Full Text] [Related]  

  • 16. Chemotherapy for low-grade gliomas: lessons and questions.
    Raizer J
    Oncology (Williston Park); 2014 Dec; 28(12):1043-4, 1051. PubMed ID: 25510804
    [No Abstract]   [Full Text] [Related]  

  • 17. Designing new drugs for high grade gliomas.
    Frosina G
    Curr Pharm Des; 2011; 17(23):2368-9. PubMed ID: 21827412
    [No Abstract]   [Full Text] [Related]  

  • 18. Managing intracranial incidental findings suggestive of low-grade glioma: learning from experience.
    Shah AH; Madhavan K; Sastry A; Komotar RJ
    World Neurosurg; 2013 Nov; 80(5):e75-7. PubMed ID: 22722044
    [No Abstract]   [Full Text] [Related]  

  • 19. The diagnostic value of high-frequency power-based diffusion-weighted imaging in prediction of neuroepithelial tumour grading.
    Chen Z; Zhou P; Lv B; Liu M; Wang Y; Wang Y; Lou X; Gui Q; He H; Ma L
    Eur Radiol; 2017 Dec; 27(12):5056-5063. PubMed ID: 28608161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailoring chemotherapy for low-grade gliomas.
    Galanis E
    Oncology (Williston Park); 2014 Dec; 28(12):1052, 1071. PubMed ID: 25510805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.